COVID-19 Omicron Human Challenge Study
Part of Infections, Lungs & breathing clinical trials.
This study is a 'human challenge' trial where healthy volunteers who have been vaccinated and have low antibody levels are deliberately exposed to a newer Omicron variant of COVID-19. The goal is to learn how the virus spreads and how to test treatments or vaccines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old
- You have had at least one COVID-19 vaccine, with the last dose at least 3 months ago
- You have antibodies against SARS-CoV-2 (from a prior infection or vaccine)
- Your antibody levels are low enough that you might still get infected (a blood test will confirm)
- You are generally healthy with no serious medical conditions, and you are a non-smoker
- You are willing to stay in quarantine for the study period and use effective contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an updated COVID-19 booster vaccine designed to improve protection for people who are older or have health conditions that increase their risk of severe COVID-19. If you qualify, you would receive one dose of the study vaccine and be monitored for safety and immune response.
This study tests a new COVID-19 vaccine (called BMI2012) in healthy adults. It aims to see if the vaccine is safe and triggers a good immune response against new variants of the virus. If you qualify, you'd receive the vaccine and be monitored over time.
This study looks at how the immune system in the body responds to different COVID-19 virus variants. It may help improve how COVID-19 is diagnosed by comparing people who are currently infected and those who are not.
This trial checks how well antibodies from COVID-19 or monkeypox vaccines or treatments work in adults. It helps researchers understand your protection level.
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
This early-phase trial tests a new drug (called B10-FC) to see if it's safe and how the body processes it. It is given once to healthy adults, and later to people with mild or moderate COVID-19 who are at higher risk of getting very sick.
Hear when a new SARS-CoV-2 (COVID-19) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.